Rhumbline Advisers Decreases Stock Holdings in AbbVie Inc. $ABBV

Rhumbline Advisers reduced its position in shares of AbbVie Inc. (NYSE:ABBV) by 1.0% in the third quarter, HoldingsChannel reports. The institutional investor owned 3,039,207 shares of the company’s stock after selling 30,676 shares during the quarter. AbbVie makes up approximately 0.6% of Rhumbline Advisers’ holdings, making the stock its 23rd biggest holding. Rhumbline Advisers’ holdings in AbbVie were worth $703,698,000 at the end of the most recent quarter.

A number of other large investors have also added to or reduced their stakes in ABBV. Ellenbecker Investment Group grew its stake in shares of AbbVie by 0.8% in the third quarter. Ellenbecker Investment Group now owns 5,334 shares of the company’s stock worth $1,235,000 after purchasing an additional 44 shares during the last quarter. Security National Bank of Sioux City Iowa IA lifted its holdings in AbbVie by 0.3% in the 3rd quarter. Security National Bank of Sioux City Iowa IA now owns 15,382 shares of the company’s stock worth $3,562,000 after buying an additional 45 shares during the period. Matthew Goff Investment Advisor LLC grew its position in shares of AbbVie by 0.3% in the 3rd quarter. Matthew Goff Investment Advisor LLC now owns 17,561 shares of the company’s stock worth $4,066,000 after buying an additional 45 shares during the last quarter. Centennial Wealth Advisory LLC increased its stake in shares of AbbVie by 2.2% during the third quarter. Centennial Wealth Advisory LLC now owns 2,089 shares of the company’s stock valued at $484,000 after buying an additional 45 shares during the period. Finally, Willner & Heller LLC increased its stake in shares of AbbVie by 0.6% during the third quarter. Willner & Heller LLC now owns 7,596 shares of the company’s stock valued at $1,759,000 after buying an additional 46 shares during the period. Institutional investors own 70.23% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on ABBV. Evercore dropped their price target on AbbVie from $232.00 to $228.00 and set an “outperform” rating for the company in a research note on Wednesday, February 4th. JPMorgan Chase & Co. raised their target price on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research report on Monday, November 3rd. Guggenheim boosted their price target on shares of AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a research report on Monday, October 20th. Raymond James Financial set a $256.00 price target on shares of AbbVie in a research note on Monday, November 3rd. Finally, BMO Capital Markets restated an “outperform” rating and issued a $258.00 price objective on shares of AbbVie in a report on Thursday, January 15th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $251.00.

AbbVie Price Performance

Shares of NYSE ABBV opened at $222.32 on Wednesday. AbbVie Inc. has a 1 year low of $164.39 and a 1 year high of $244.81. The firm has a 50-day moving average of $223.67 and a 200 day moving average of $220.29. The stock has a market cap of $392.93 billion, a P/E ratio of 94.20, a price-to-earnings-growth ratio of 0.78 and a beta of 0.35.

AbbVie (NYSE:ABBV) last announced its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The business had revenue of $16.62 billion during the quarter, compared to the consensus estimate of $16.39 billion. During the same quarter last year, the firm earned $2.16 earnings per share. The business’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Research analysts expect that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.